Skip to main content
. 2021 Aug 31;10(20):7079–7088. doi: 10.1002/cam4.4241

FIGURE 2.

FIGURE 2

Cumulative event rates of cancer‐related death (A) and all‐cause mortality (B), and cumulative incidence function using the Fine and Gray method of major bleeding (C) and gastrointestinal bleeding (D) of patients with dabigatran or rivaroxaban treatments in the IPTW‐adjusted cohort. IPTW, inverse probability of treatment weighting